<DOC>
	<DOCNO>NCT03038100</DOCNO>
	<brief_summary>This Phase III , global , double-blind , two-arm , randomize study design evaluate efficacy safety atezolizumab administer paclitaxel + carboplatin + bevacizumab compare placebo + paclitaxel + carboplatin + bevacizumab participant Stage III Stage IV ovarian ( OC ) , fallopian tube ( FTC ) , primary peritoneal cancer ( PPC ) macroscopic residual disease postoperatively ( i.e. , primary tumor reductive surgery ) undergo neoadjuvant therapy follow interval surgery .</brief_summary>
	<brief_title>A Study Atezolizumab Versus Placebo Combination With Paclitaxel , Carboplatin , Bevacizumab Participants With Newly-Diagnosed Stage III Stage IV Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participants receive histologic diagnosis epithelial ovarian cancer ( EOC ) , peritoneal primary carcinoma , fallopian tube cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy great ( &gt; ) 12 week For participant receive therapeutic anticoagulation : stable anticoagulant regimen Availability representative formalinfixed , paraffinembedded ( FFPE ) tumor specimen paraffin block ( prefer ) least 20 unstained slide ( detailed tissue requirement screen ) Received current diagnosis borderline epithelial ovarian tumor ( formerly tumor low malignant potential ) Have recurrent invasive epithelial ovarian , fallopian tube , primary peritoneal cancer treat surgery ( example [ e.g . ] , participant Stage IA Stage IB epithelial ovarian fallopian tube cancer ) Have nonepithelial ovarian tumor ( e.g. , germ cell tumor , sex cord stromal tumor ) Received prior radiotherapy portion abdominal cavity pelvis Received prior chemotherapy abdominal pelvic tumor include neoadjuvant chemotherapy ( NACT ) ovarian , primary peritoneal fallopian tube cancer Received biological and/or target therapy ( include limit vaccine , antibody , tyrosine kinase inhibitor ) hormonal therapy management and/or treatment epithelial ovarian peritoneal primary cancer Have synchronous primary endometrial cancer Have prior history primary endometrial cancer , except : Stage IA cancer ; superficial myometrial invasion , without lymphovascular invasion ; grade less ( &lt; ) 3 poorly differentiate subtypes , include papillary serous , clear cell International Federation Gynecological Oncologists ( FIGO ) Grade 3 lesion With exception nonmelanoma skin cancer specific malignancy note , invasive malignancy evidence cancer present within last 5 year previous cancer treatment contraindicate protocol therapy Have know hypersensitivity allergy biopharmaceutical agent produce Chinese hamster ovary cell component atezolizumab and/or bevacizumab formulation Undergo major surgical procedure within 28 day prior randomization , anticipation need major surgical procedure course study except participant receive NACT need interval surgery Have prior allogeneic bone marrow transplantation solid organ transplant Have disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result Have approve investigational anticancer therapy , include chemotherapy hormonal therapy , exception : Hormonereplacement therapy oral contraceptive Are administer treatment investigational agent participation another clinical study anticancer therapeutic intent Have core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior first dose bevacizumab Have know sensitivity component bevacizumab Have know sensitivity component paclitaxel</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>